This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of cosmetic polynucleotides, cosmetic primary transcripts and cosmetic mmRNA molecules.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Transgenic swine that express human coagulation factors, e.g., human coagulation factor VII, and/or one or more of human coagulation factors II, X and XII, and do not express the corresponding porcine coagulation factor or factors, as well as cells, tissues and organs derived therefrom, and their use in transplantation procedures.

The present invention relates to a bicyclic inhibitor of the coagulation enzyme activated factor XII (FXIIa) comprising or consisting of the peptide) (X.sup.1)(X.sup.2)(X.sup.3).sub.n(X.sup.4)RL(X.sup.5)(X.sup.6).sub.m(X.sup.7)(X.sup.9).sub.l(X.sup.10)(X.sup.11)(X.sup.12)(X.sup.13)(X.sup.14).sub.k(X.sup.15)(X.sup.16), wherein (X.sup.1) is present or absent and, if present, is an amino acid; (X.sup.2) is an amino acid with a side chain; (X.sup.3) is an amino acid and n is between 0 and 3, preferably 0 or 1 and most preferably 0; (X.sup.4) is an aliphatic L-amino acid or a cyclic L-amino acid, preferably L, P or an aromatic L-amino acid, and most preferably an aromatic L-amino acid; (X.sup.5) is an amino acid; (X.sup.6) is an amino acid and m is between 0 and 3, preferably 0 or 1 and most preferably 0; (X.sup.7) is an amino acid with a side chain; (X.sup.9) is an amino acid and l is between 0 and 3, preferably 0 or 1 and most preferably 0; (X.sup.10) is an amino acid; (X.sup.11) is an amino acid, preferably Q; (X.sup.12) is a hydrophobic L-amino acid, preferably an aliphatic L-amino acid, and is most preferably L; (X.sup.13) is an amino acid; (X.sup.14) is an amino acid and k is between 0 and 3, preferably 0 or 1 and most preferably 0, (X.sup.15) is an amino acid with a side chain; and (X.sup.16) is present or absent and, if present, is an amino acid; and wherein the side chains of (X.sup.2), (X.sup.7) and (X.sup.15) are connected via a connecting molecule, said connecting molecule having at least three functional groups, each functional group forming a covalent bond with one of the side chains of (X.sup.2), (X.sup.7) and (X.sup.15).

The invention relates to cosmetic mRNAs encoding elastin, and methods of using such mRNAs.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.